Compare S&P Global Inc (SPGI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs TG Therapeutics Inc — how do they compare? S&P Global Inc trades at $431.77 (market cap $132.71B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: S&P Global Inc is far larger — about 16.1× TG Therapeutics Inc's market cap, and S&P Global Inc pays a 0.87% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SPGI | TGTX | |
|---|---|---|
Market Cap | $132.71B | $8.26B |
Sector | Financials | Health |
52-Week High | $534.79 | $59.06 |
52-Week Low | $370.42 | $26.39 |
Enterprise Value | $144.68B | $8.50B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $431.26, down 4.34% on the day, amid a generally bullish technical setup with strong analyst support. The company reported robust fundamentals with 2025 revenue of $15.34B and net income of $4.47B, yielding a 30.36% net margin. Recent corporate developments include the spin-off of its mobility business and new product launches in digital asset indexing and ETF analytics, signaling strategic focus and innovation.
The outlook remains positive given strong profitability, recurring revenue model, and Wall Street's consensus price target of $532.10, implying significant upside. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Earnings growth and AI-driven data demand present the primary catalysts for shareholder value appreciation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
